Discover what could
be in reach
YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.1
See full Indication for accelerated approval below.
Beau, 6 years old,
taking YUVIWEL as
part of a clinical trial.
taking YUVIWEL as
part of a clinical trial.
Continuous CNP
exposure in a
once‑weekly dose1,2
Learn about TransCon®
Demonstrated improvements in linear growth1*
Explore efficacyResources for you and your practice
Go to resources*In a 2:1 randomized, double-blind, placebo-controlled 52-week study (N=84), treatment with once-weekly YUVIWEL resulted in a least-squares mean treatment difference in annualized growth velocity of 1.5 cm/year.1
CNP=C-type natriuretic peptide.
Connect with us
Interested in learning more about YUVIWEL for your patients with achondroplasia?
Please fill out the form below for updates and resources.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Risk of Low Blood Pressure
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
INDICATION AND USAGE
YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Risk of Low Blood Pressure
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
ADVERSE REACTIONS
The most common adverse reactions (≥5%) are vomiting, injection site reaction, pain in extremity, and nausea.
SPECIFIC POPULATIONS
Pregnancy and Lactation
There are no available data on the use of YUVIWEL in pregnant women, or data on the presence of YUVIWEL in human milk, the potential effects on milk production or the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YUVIWEL and any potential adverse effects on the breastfed infant from YUVIWEL or from the underlying maternal condition.
Renal Impairment
YUVIWEL is not recommended for patients with moderate or severe renal impairment.
You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.
Please see full Prescribing Information for YUVIWEL.
FDA=Food and Drug Administration.
References: 1. Yuviwel. Prescribing information. Ascendis Pharma, Inc.; 2026. 2. Breinholt VM, Rasmussen CE, Mygind PH, et al. TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias. J Pharmacol Exp Ther. 2019;370(3):459-471.